BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18953713)

  • 1. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine.
    Thimme R; Neumann-Haefelin C; Boettler T; Blum HE
    Biol Chem; 2008 May; 389(5):457-67. PubMed ID: 18953713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the development of vaccines for hepatitis C virus infection.
    Ghasemi F; Rostami S; Meshkat Z
    World J Gastroenterol; 2015 Nov; 21(42):11984-2002. PubMed ID: 26576087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.
    Dahari H; Feinstone SM; Major ME
    Gastroenterology; 2010 Sep; 139(3):965-74. PubMed ID: 20621699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV.
    Shoukry NH
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence.
    Burke KP; Cox AL
    Immunol Res; 2010 Jul; 47(1-3):216-27. PubMed ID: 20066508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis.
    Lanford RE; Walker CM; Lemon SM
    ILAR J; 2017 Dec; 58(2):172-189. PubMed ID: 29045731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Success and failure of virus-specific T cell responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Dig Dis; 2011; 29(4):416-22. PubMed ID: 21894013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity and hepatitis C: a review.
    Terilli RR; Cox AL
    Curr HIV/AIDS Rep; 2013 Mar; 10(1):51-8. PubMed ID: 23180007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.
    Swann RE; Mandalou P; Robinson MW; Ow MM; Foung SK; McLauchlan J; Patel AH; Cramp ME
    J Viral Hepat; 2016 Nov; 23(11):873-880. PubMed ID: 27405885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.
    Kuniholm MH; Xie X; Anastos K; Kaplan RC; Xue X; Kovacs A; Peters MG; Seaberg EC; French AL; Young MA; Augenbraun M; Martinson JA; Bush KA; Landay AL; Strickler HD
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):295-303. PubMed ID: 25314250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus.
    Kuniholm MH; Anastos K; Kovacs A; Gao X; Marti D; Sette A; Greenblatt RM; Peters M; Cohen MH; Minkoff H; Gange SJ; Thio CL; Young MA; Xue X; Carrington M; Strickler HD
    Genes Immun; 2013; 14(5):330-5. PubMed ID: 23636221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase.
    Mostowy R; Kouyos RD; Hoof I; Hinkley T; Haddad M; Whitcomb JM; Petropoulos CJ; Keşmir C; Bonhoeffer S
    PLoS Comput Biol; 2012; 8(5):e1002525. PubMed ID: 22654656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.
    Haynes BF; Kelsoe G; Harrison SC; Kepler TB
    Nat Biotechnol; 2012 May; 30(5):423-33. PubMed ID: 22565972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection.
    Rivière Y; Montange T; Janvier G; Marnata C; Durrieu L; Chaix ML; Isaguliants M; Launay O; Bresson JL; Pol S
    Virol J; 2012 Mar; 9():76. PubMed ID: 22455516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands.
    Wölk B; Trautwein C; Büchele B; Kersting N; Blum HE; Rammensee HG; Cerny A; Stevanovic S; Moradpour D; Brass V
    PLoS One; 2012; 7(1):e29286. PubMed ID: 22235280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
    Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
    Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a multiplex bead-based assay for detection of hepatitis C virus.
    Fonseca BP; Marques CF; Nascimento LD; Mello MB; Silva LB; Rubim NM; Foti L; Silva ED; Ferreira AG; Krieger MA
    Clin Vaccine Immunol; 2011 May; 18(5):802-6. PubMed ID: 21346054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic coinfection with multiple viral subtypes in acute hepatitis C.
    Smith JA; Aberle JH; Fleming VM; Ferenci P; Thomson EC; Karayiannis P; McLean AR; Holzmann H; Klenerman P
    J Infect Dis; 2010 Dec; 202(12):1770-9. PubMed ID: 21067369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences.
    Yu C; Boon D; McDonald SL; Myers TG; Tomioka K; Nguyen H; Engle RE; Govindarajan S; Emerson SU; Purcell RH
    J Virol; 2010 Nov; 84(21):11264-78. PubMed ID: 20739520
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.